These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 1961278)

  • 41. Medicare and Medicaid statistical supplement, 1996. U.S. Department of Health and Human Services, Health Care Financing Administration.
    Health Care Financ Rev Stat Suppl; 1996; ():1-472. PubMed ID: 10162839
    [No Abstract]   [Full Text] [Related]  

  • 42. HCFA, Stark eye Medicare ESRD expenditures.
    Koska MT
    Hospitals; 1988 May; 62(10):84. PubMed ID: 3283025
    [No Abstract]   [Full Text] [Related]  

  • 43. Participants, analysts share preliminary data from the ESRD managed care demonstration project.
    Neumann ME
    Nephrol News Issues; 2001 Jul; 15(8):15-6. PubMed ID: 12099225
    [No Abstract]   [Full Text] [Related]  

  • 44. The economic cost of ESRD and Medicare spending for alternative modalities of treatment. United States Renal Data System.
    Am J Kidney Dis; 1998 Aug; 32(2 Suppl 1):S118-31. PubMed ID: 9713414
    [No Abstract]   [Full Text] [Related]  

  • 45. Study of the Medicare End-Stage Renal Disease program.
    Rettig RA
    Am J Kidney Dis; 1990 May; 15(5):491-3. PubMed ID: 2185628
    [No Abstract]   [Full Text] [Related]  

  • 46. Deliberations on and myths about OBRA '87 psychopharmacological medication regulations.
    Kidder SW
    J Am Med Dir Assoc; 2003; 4(5):268-73. PubMed ID: 12959656
    [No Abstract]   [Full Text] [Related]  

  • 47. Linking reimbursement and quality.
    Neumann ME
    Nephrol News Issues; 2004 Oct; 18(11):21-4. PubMed ID: 15551611
    [No Abstract]   [Full Text] [Related]  

  • 48. Proposed conditions for coverage directed toward dialysis facilities.
    Smetanka S
    Health Care Law Mon; 2005 Apr; ():3-11. PubMed ID: 15895752
    [No Abstract]   [Full Text] [Related]  

  • 49. The use of rehabilitation services by patients with chronic renal failure: results from the National Kidney Dialysis and Kidney Transplantation Study.
    Evans RW; Manninen DL; Garrison LP; Hart LG
    AANNT J; 1983 Oct; 10(6):19-25. PubMed ID: 6360186
    [No Abstract]   [Full Text] [Related]  

  • 50. IOM says: X-ray mammography remains the gold standard in breast cancer screening technology.
    Rollins G
    Rep Med Guidel Outcomes Res; 2001 Apr; 12(8):1-2, 5. PubMed ID: 12108453
    [No Abstract]   [Full Text] [Related]  

  • 51. Tackling pay-for-performance: current and future challenges.
    Bhat P; Bhat JG
    Nephrol News Issues; 2012 Jan; 26(1):27-9. PubMed ID: 22359962
    [No Abstract]   [Full Text] [Related]  

  • 52. Understanding financial risk models: Implicationsfor nephrology practices and dialysis centers.
    Cellini GL
    Nephrol News Issues; 2016 Mar; 30(3):26-8, 30-3. PubMed ID: 27169216
    [No Abstract]   [Full Text] [Related]  

  • 53. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO?
    Besarab A; McCrea JB
    ASAIO J; 1993; 39(1):11-8. PubMed ID: 8439674
    [No Abstract]   [Full Text] [Related]  

  • 54. Will the bundle improve the way care is delivered?
    Neumann ME
    Nephrol News Issues; 2010 Jan; 24(1):8. PubMed ID: 20196495
    [No Abstract]   [Full Text] [Related]  

  • 55. Geographic adjustment in Medicare payment. Institute of Medicine report offers price change recomendations.
    Ferman JH
    Healthc Exec; 2011; 26(5):70-1. PubMed ID: 21932623
    [No Abstract]   [Full Text] [Related]  

  • 56. Integrated care models: if patients benefit, so will bottom line.
    Neumann ME
    Nephrol News Issues; 2012 Sep; 26(10):8. PubMed ID: 23033620
    [No Abstract]   [Full Text] [Related]  

  • 57. GOP deficit plan gone ... but cuts to Medicare, Medicaid likely to stay.
    Daly R
    Mod Healthc; 2011 May; 41(22):8-9. PubMed ID: 21717656
    [No Abstract]   [Full Text] [Related]  

  • 58. The politics of health cost containment: end-stage renal disease.
    Rettig RA
    Bull N Y Acad Med; 1980; 56(1):115-38. PubMed ID: 6986928
    [No Abstract]   [Full Text] [Related]  

  • 59. Cyclosporine and the financial plight of organ transplant recipients.
    Helgeson MD
    Nephrol News Issues; 1992 Aug; 6(8):12, 16. PubMed ID: 1407062
    [No Abstract]   [Full Text] [Related]  

  • 60. From fee-for-service to capitation: factors driving ESRD reimbursement system change.
    Day LM
    Nephrol News Issues; 1997 Apr; 11(4):22-3, 31. PubMed ID: 9287685
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.